Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399

Watchlist Manager
Jiangsu Bioperfectus Technologies Co Ltd Logo
Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399
Watchlist
Price: 64.8 CNY -1.22% Market Closed
Market Cap: 5.4B CNY

Jiangsu Bioperfectus Technologies Co Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Jiangsu Bioperfectus Technologies Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399
Operating Income
-ÂĄ76.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Operating Income
ÂĄ2.6B
CAGR 3-Years
-8%
CAGR 5-Years
0%
CAGR 10-Years
N/A
S
Shanghai Conant Optical Co Ltd
HKEX:2276
Operating Income
ÂĄ525.5m
CAGR 3-Years
28%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
Operating Income
ÂĄ827.4m
CAGR 3-Years
-12%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Operating Income
ÂĄ2B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
22%
Intco Medical Technology Co Ltd
SZSE:300677
Operating Income
ÂĄ991.9m
CAGR 3-Years
15%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
No Stocks Found

Jiangsu Bioperfectus Technologies Co Ltd
Glance View

Market Cap
5.4B CNY
Industry
Health Care

Jiangsu Bioperfectus Technologies Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company is headquartered in Taizhou, Jiangsu and currently employs 765 full-time employees. The company went IPO on 2019-12-05. The firm's products mainly include in vitro diagnostic reagents, supporting testing instruments and in vitro testing services. Its products are mainly used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, as well as prenatal and postnatal care management. The firm mainly conducts its businesses in domestic and overseas markets.

Intrinsic Value
61.95 CNY
Overvaluation 4%
Intrinsic Value
Price

See Also

What is Jiangsu Bioperfectus Technologies Co Ltd's Operating Income?
Operating Income
-76.7m CNY

Based on the financial report for Sep 30, 2025, Jiangsu Bioperfectus Technologies Co Ltd's Operating Income amounts to -76.7m CNY.

What is Jiangsu Bioperfectus Technologies Co Ltd's Operating Income growth rate?
Operating Income CAGR 1Y
65%

Over the last year, the Operating Income growth was 65%.

Back to Top